Endogenous antibody response to SARS-CoV-2 in patients who received monoclonal antibodies against COVID-19: A systematic review

Lombardi, A.; Azzara, C.; Renisi, G.; Viero, G.; Gori, A.; Bandera, A.

Lombardi, A.; Azzara, C.; Renisi, G.; Viero, G.; Gori, A.; Bandera, A..

Clinical Immunology Communications ; 2:106-109, 2022.

Article in English | EMBASE | ID: covidwho-2269581

ABSTRACT

ABSTRACT

Passive immunization with mAbs has been employed in COVID-19. We performed a systematic review of the literature assessing the endogenous humoral immune response against SARS-CoV-2 in patients treated with mAbs. Administration of mAbs in seronegative patients led to a reduction in both antibody titres and neutralizing activity against the virus.Copyright © 2022

Keywords

Endogenous immune response, Monoclonal antibodies, Neutralization, SARS-CoV-2, Spike protein, antibody response, antibody titer, article, coronavirus disease 2019/dt [Drug Therapy], human, monotherapy, passive immunization, SARS-CoV-2 Beta, SARS-CoV-2 pseudovirus, seroconversion, systematic review, virus neutralization, bamlanivimab/cm [Drug Comparison], bamlanivimab/dt [Drug Therapy], bamlanivimab plus etesevimab/cm [Drug Comparison], bamlanivimab plus etesevimab/dt [Drug Therapy], casirivimab plus imdevimab/cm [Drug Comparison], casirivimab plus imdevimab/dt [Drug Therapy], coronavirus nucleocapsid protein, coronavirus spike glycoprotein, immunoglobulin G antibody/ec [Endogenous Compound], immunoglobulin M antibody/ec [Endogenous Compound], monoclonal antibody/dt [Drug Therapy], placebo, SARS-CoV-2 vaccine

Fulltext

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Reviews / Systematic review/Meta Analysis Language: English Journal: Clinical Immunology Communications Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google